Thalidomide reduces IL-18, IL-8 and TNF-α release from alveolar macrophages in interstitial lung disease

European Respiratory Journal

Volumn 28, Issue 4, 2006, Pages 824-831

  Ye, Q ^a   Chen, B ^a   Tong, Z ^a   Nakamura, S ^c   Sarria, R ^d   Costabel, U ^a   Guzman, J ^b,c  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c NARA MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Alveolar macrophage; Cytokine; Interstitial lung disease; Thalidomide

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ALLERGIC PNEUMONITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; INHIBITION KINETICS; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; LUNG SARCOIDOSIS; MALE; PRIORITY JOURNAL; CYTOLOGY; DRUG EFFECT; METABOLISM; MIDDLE AGED;

AGED; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIPOPOLYSACCHARIDES; LUNG DISEASES, INTERSTITIAL; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; THALIDOMIDE;

EID: 33847402332     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00131505     Document Type: Article

References (37)

1. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004; 363: 1802-1811.
2. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
3. Tavares JL, Wangoo A, Dilworth P, Marshall B, Kotecha S, Shaw RJ. Thalidomide reduces tumor necrosis factor-α production by human alveolar macrophages. Respir Med 1997; 91: 31-39.
4. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-1680.
5. Moller DR, Wysocka M, Greenlee BM, et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997; 159: 5157-5161.
6. Verbon A, Juffermans NP, Speelman P, et al. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrob Agents Chemother 2000; 44: 2286-2290.
7. McHugh SM, Rifkin IR, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995; 99: 160-167.
8. Rowland TL, McHugh SM, Deighton J, Dearman RJ, Ewan PW, Kimber I. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology 1998; 40: 11-20.
9. Stirling DI. Thalidomide and its impact in dermatology. Semin Cutan Med Surg 1998; 17: 231-242.
10. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O. Treatment of refractory rheumatoid arthritis - the thalidomide experience. J Rheumatol 1989; 16: 158-163.
11. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trail. Gastroenterology 1999; 117: 1271-1277.
12. Tramontana JM, Utaipat U, Molloy A, et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995; 1: 384-397.
13. Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE. Thalidomide for chronic sarcoidosis. Chest 2002; 122:227-232.
14. Uthoff K, Zehr KJ, Gaudin PB, et al. Thalidomide as replacement for steroids in immunosuppression after lung transplantation. Ann Thorac Surg 1995; 59: 277-282.
15. Barlogie B, Tricot G, Anaissie E. Thalidomide in the management of multiple myeloma. Semin Oncol 2001; 28: 577-582.
16. American Thoracic Society, Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160: 736-755.
17. Costabel U. The alveolitis of hypersensitivity pneumonitis. Eur Respir J 1988; 1: 5-9.
18. Baughman RP, Strohofer SA, Buchsbaum J, Lower EE. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990; 115: 36-42.
19. Shigehara K, Shijubo N, Ohmichi M, et al. IL-12 and IL-18 are increased and stimulate IFN-γ production in sarcoid lungs. J Immunol 2001; 166: 642-649.
20. Chen BM, Tong ZH, Nakamura S, Costabel U, Guzman J. Production of IL-12, IL-18 and TNF-α by alveolar macrophages in hypersensitivity pneumonitis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 199-203.
21. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-151.
22. Keane MP, Arenberg DA, Lynch JP III, et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997; 159: 1437-1443.
23. Ebina M, Shimizukawa M, Shibata N, et al. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004; 169: 1203-1208.
24. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society (ATS) and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165: 277-304.
25. Akira S. The role of IL-18 in innate immunity. Curr Opin Immunol 2000; 12: 59-63.
26. Taha RA, Minshall EM, Olivernstein R, et al. Increased expression of IL-12 receptor mRNA in active pulmonary tuberculosis and sarcoidosis. Am J Respir Crit Care Med 1999; 160: 1119-1123.
27. Moller DR, Forman JD, Liu MC, et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996; 56: 4952-4960.
28. Nguyen YT, Dupuy A, Cordoliani F, et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 2004; 50: 235-241.
29. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003; 29: 1111-1118.
30. Wild JS, Sigounas A, Sur N, et al. IFN-γ-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia in a mouse model of allergic asthma. J Immunol 2000; 164: 2701-2710.
31. Abdi K. IL-12: the role of p40 versus p75. Scand J Immunol 2002; 56: 1-11.
32. Moreira AL, Tsenova-Berkova L, Wang J, et al. Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. Tuber Lung Dis 1997; 78: 47-55.
33. Yagyu T, Kobayashi H, Matsuzaki H, et al. Thalidomide inhibits tumor necrosis factor-α-induced interleukin-8 expression in endometriotic stromal cells, possibly through suppression of nuclear factor-κB activation. J Clin Endocrinol Metab 2005; 90: 3017-3021.
34. Miyazaki Y, Araki K, Vesin C, et al. Expression of a tumor necrosis factor-α transgene in murine lung model of progressive pulmonary fibrosis. J Clin Invest 1995; 96: 250-259.
35. Peao MND, Aguas AP, de Sa CM, Grande NR. Neoformation of blood vessels in association with rat lung fibrosis induced by bleomycin. Anat Rec 1994; 238: 57-67.
36. Simler NR, Brenchley PE, Horrocks AW, Greaves SM, Hasleton PS, Egan JJ. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 2004; 59: 581-585.
37. Gudmundsson G, Hunninghake GW. Interferon-γ is necessary for the expression of hypersensitivity pneumonitis. J Clin Invest 1997; 99: 2386-2390.